What should I avoid while taking Disulfiram 500mg tablets?

Avoid alcohol. Avoid alcohol for up to 14 days after discontinuation. Take with or without food. The absorption is unaffected by food. (Source: DrugBank, licensed under CC BY-NC 4.0)

Do I need a prescription for Disulfiram 500mg tablets?

Disulfiram 500mg tablets is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Disulfiram 500mg tablets?

Disulfiram 500mg tablets is the generic name. It is available under brand names including: Esperal 500mg tablets. (Source: NHS dm+d — Actual Medicinal Products)

Disulfiram 500mg tablets

Prescription only

Requires a prescription from a doctor or prescriber

Tablet

500mg

Oral

A carbamate derivative used as an alcohol deterrent.

Active ingredients:

Disulfiram

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC N07BB01

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Disulfiram

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Disulfiram

Source: MHRA Products DatabaseOGL 3.0

Updated 6 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Disulfiram

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Disulfiram

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Disulfiram on the MHRA register

Esperal 500mg tablets

Imported (France)

None

Imported

Source: NHS dm+dOGL 3.0

Updated 4 months ago(1 Mar 2026)

Daily dose

WHO defined daily dose (DDD)

200 mg

Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.

Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.

Therapeutically similar medicines

10 similar

Naltrexone 25mg/5ml oral solution

Oral solution

25mg/5ml

Same therapeutic group

Naltrexone 2.5mg capsules

Capsule

2.5mg

Same therapeutic group

Disulfiram 250mg tablets

Tablet

250mg

Same therapeutic group

Nalmefene 18mg tablets

Tablet

18mg

Same therapeutic group

Naltrexone 1.5mg/5ml oral solution

Oral solution

1.5mg/5ml

Same therapeutic group

Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

NHS prescribing volume and spending trends

Loading prescribing data...

Guidelines from the National Institute for Health and Care Excellence

NICE clinical guidance(2)

Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

CG115

Clinical guideline

Updated Oct 2014

Alcohol-use disorders: diagnosis and management (QS11)

QS11

Quality standard

Updated Jul 2023

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & safety information

Official UK regulator monitoring and safety alerts

MHRA drug safety updates

UK regulator alerts and supply notices

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).

Codes for healthcare professionals and prescribing systems

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

42270511000001108

dm+d ID

42270511000001108

VTM (Virtual Therapeutic Moiety)

775664007

VMP (Virtual Medicinal Product)

42270511000001108

BNF code (NHS dm+d)

04100100

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

N07BB01

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Academic studies and reviews for this medicine's active substance

Showing the 50 most relevant studies.

Reviews & meta-analyses: 11 · Randomised trials: 3 · 1964–2026

Sort

Disulfiram Efficacy in the Treatment of Alcohol Dependence: A Meta-Analysis

Marilyn D. Skinner, Pierre Lahmek, Héloïse Pham, et al.

PLoS ONE, 2014

Meta-analysis

Highly cited for its field

Cited by 344

Alcohol Deterrents
Alcoholism
Cocaine

A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence

Э. Лааксонен, Anja Koski‐Jännes, Mikko Salaspuro, et al.

Alcohol and Alcoholism, 2007

Randomised trial

Highly cited for its field

Cited by 148

Acamprosate
Alcoholism
Disulfiram

Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence

Beáta-Mária Benkő, Neuza Sofia De Brito Parreirinha, István Sebe, et al.

iScience, 2026

Systematic review

A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites

Benny Johansson

Acta Psychiatrica Scandinavica, 1992

Review

Cited by 353

Acetaldehyde
Alcoholism
Disulfiram

The disulfiram--ethanol reaction: a review.

Trevor M. Kitson

Journal of Studies on Alcohol, 1977

Review

Highly cited for its field

Cited by 233

Alcohol Drinking
Acetaldehyde
Ethanol

Disulfiram: a novel repurposed drug for cancer therapy

Lu Chen, Xinyan Li, Yongya Ren, et al.

Cancer Chemotherapy and Pharmacology, 2021

Review

Highly cited for its field

Cited by 157

Antineoplastic Agents
Disulfiram
Neoplasms

Disulfiram: Mechanisms, Applications, and Challenges

Jenna Lanz, Nicholas Biniaz-Harris, Maria Kuvaldina, et al.

Antibiotics, 2023

Review

Highly cited for its field

Cited by 109

A systematic review of disulfiram as an antibacterial agent: What is the evidence?

J. E. Meneguello, L. S. Murase, J. P. D. de Souza, et al.

International journal of antimicrobial agents, 2022

Systematic review

Cited by 13

Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens

Yao Lu, Qingqing Pan, Wenxia Gao, et al.

Biomaterials, 2021

Review

Highly cited for its field

Cited by 139

Disulfiram
Neoplasms
Copper

Pharmacogenetic Randomized Trial for Cocaine Abuse: Disulfiram and Dopamine β-Hydroxylase

Thomas R. Kosten, Guiying Wu, Wen Huang, et al.

Biological Psychiatry, 2012

Randomised trial

Highly cited for its field

Cited by 107

Disulfiram
Dopamine beta-Hydroxylase
Genotype

Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

None known

Half-life

Not available

Mechanism

Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alco…

Food interactions

2 warnings

Human targets

3 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

80 to 90%

Disulfiram is absorbed slowly from the gastrointestinal tract (80 to 90% of oral dose).

Metabolism

Hepatic.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.

Properties:

solid

Avg. mass: 296.54 Da

DrugBank indication

For the treatment and management of chronic alcoholism

Also known as(47)

1,1'-dithiobis(N,N-diethylthioformamide)

bis(diethylthiocarbamoyl) disulfide

Disulfiram

N,N,N',N'-tetraethylthiuram disulfide

Tetraethylthioperoxydicarbonic diamide

Tetraethylthiuram disulfide

Tetraethylthiuram disulphide

1.14.17.1

Molecular properties(17)

Drug interactions(892)

Known interactions with other medications. Always consult a healthcare professional.

Troglitazone

Moderate

DB00197

Troglitazone may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Erythromycin

Unknown severity

DB00199

The serum concentration of Disulfiram can be increased when it is combined with Erythromycin.

Check this interaction

Reserpine

Moderate

DB00206

Reserpine may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Progesterone

Moderate

DB00396

Progesterone may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Chlorpromazine

Moderate

DB00477

Chlorpromazine may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Celecoxib

Moderate

DB00482

Celecoxib may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Cimetidine

Moderate

DB00501

Cimetidine may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Bosentan

Moderate

DB00559

Bosentan may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Ethinylestradiol

Moderate

DB00977

Ethinylestradiol may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Glyburide

Moderate

DB01016

Glyburide may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Ursodeoxycholic acid

Moderate

DB01586

Ursodeoxycholic acid may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Cholic Acid

Moderate

DB02659

Cholic Acid may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Fusidic acid

Moderate

DB02703

Fusidic acid may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Simeprevir

Moderate

DB06290

Simeprevir may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Lenvatinib

Moderate

DB09078

Lenvatinib may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Letermovir

Moderate

DB12070

The metabolism of Disulfiram can be decreased when combined with Letermovir.

Check this interaction

Valinomycin

Moderate

DB14057

Valinomycin may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Olmesartan

Moderate

DB00275

Olmesartan may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Pralsetinib

Moderate

DB15822

Pralsetinib may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Quinidine

Moderate

DB00908

Quinidine may decrease the excretion rate of Disulfiram which could result in a higher serum level.

Check this interaction

Phenytoin

Unknown severity

DB00252

The serum concentration of Phenytoin can be increased when it is combined with Disulfiram.

Check this interaction

Fosphenytoin

Unknown severity

DB01320

The serum concentration of Fosphenytoin can be increased when it is combined with Disulfiram.

Check this interaction

Caffeine

Unknown severity

DB00201

The serum concentration of Caffeine can be increased when it is combined with Disulfiram.

Check this interaction

Theophylline

Unknown severity

DB00277

The serum concentration of Theophylline can be increased when it is combined with Disulfiram.

Check this interaction

Dyphylline

Unknown severity

DB00651

The serum concentration of Dyphylline can be increased when it is combined with Disulfiram.

Check this interaction

Pentoxifylline

Unknown severity

DB00806

The serum concentration of Pentoxifylline can be increased when it is combined with Disulfiram.

Check this interaction

Mercaptopurine

Unknown severity

DB01033

The serum concentration of Mercaptopurine can be increased when it is combined with Disulfiram.

Check this interaction

Aminophylline

Unknown severity

DB01223

The serum concentration of Aminophylline can be increased when it is combined with Disulfiram.

Check this interaction

Oxtriphylline

Unknown severity

DB01303

The serum concentration of Oxtriphylline can be increased when it is combined with Disulfiram.

Check this interaction

Theobromine

Unknown severity

DB01412

The serum concentration of Theobromine can be increased when it is combined with Disulfiram.

Check this interaction

Fenethylline

Unknown severity

DB01482

The serum concentration of Fenethylline can be increased when it is combined with Disulfiram.

Check this interaction

8-azaguanine

Unknown severity

DB01667

The serum concentration of 8-azaguanine can be increased when it is combined with Disulfiram.

Check this interaction

7,9-Dimethylguanine

Unknown severity

DB01978

The serum concentration of 7,9-Dimethylguanine can be increased when it is combined with Disulfiram.

Check this interaction

Xanthine

Unknown severity

DB02134

The serum concentration of Xanthine can be increased when it is combined with Disulfiram.

Check this interaction

7-Deazaguanine

Unknown severity

DB02245

The serum concentration of 7-Deazaguanine can be increased when it is combined with Disulfiram.

Check this interaction

Guanine

Unknown severity

DB02377

The serum concentration of Guanine can be increased when it is combined with Disulfiram.

Check this interaction

9-Methylguanine

Unknown severity

DB02489

The serum concentration of 9-Methylguanine can be increased when it is combined with Disulfiram.

Check this interaction

Peldesine

Unknown severity

DB02568

The serum concentration of Peldesine can be increased when it is combined with Disulfiram.

Check this interaction

Hypoxanthine

Unknown severity

DB04076

The serum concentration of Hypoxanthine can be increased when it is combined with Disulfiram.

Check this interaction

9-Deazaguanine

Unknown severity

DB04356

The serum concentration of 9-Deazaguanine can be increased when it is combined with Disulfiram.

Check this interaction

Propentofylline

Unknown severity

DB06479

The serum concentration of Propentofylline can be increased when it is combined with Disulfiram.

Check this interaction

Valomaciclovir

Unknown severity

DB06575

The serum concentration of Valomaciclovir can be increased when it is combined with Disulfiram.

Check this interaction

3-isobutyl-1-methyl-7H-xanthine

Unknown severity

DB07954

The serum concentration of 3-isobutyl-1-methyl-7H-xanthine can be increased when it is combined with Disulfiram.

Check this interaction

Uric acid

Unknown severity

DB08844

The serum concentration of Uric acid can be increased when it is combined with Disulfiram.

Check this interaction

Doxofylline

Unknown severity

DB09273

The serum concentration of Doxofylline can be increased when it is combined with Disulfiram.

Check this interaction

6-O-benzylguanine

Unknown severity

DB11919

The serum concentration of 6-O-benzylguanine can be increased when it is combined with Disulfiram.

Check this interaction

Lisofylline

Unknown severity

DB12406

The serum concentration of Lisofylline can be increased when it is combined with Disulfiram.

Check this interaction

Lobucavir

Unknown severity

DB12531

The serum concentration of Lobucavir can be increased when it is combined with Disulfiram.

Check this interaction

Cafedrine

Unknown severity

DB12926

The serum concentration of Cafedrine can be increased when it is combined with Disulfiram.

Check this interaction

Theodrenaline

Unknown severity

DB12927

The serum concentration of Theodrenaline can be increased when it is combined with Disulfiram.

Check this interaction

Showing 50 of 892 interactions

Food & lifestyle interactions

Avoid Alcohol

Avoid alcohol. Avoid alcohol for up to 14 days after discontinuation.

Advice

Take with or without food. The absorption is unaffected by food.

Toxicity & overdose

LD₅₀=8.6g/kg (orally in rats). Symptoms of overdose include irritation, slight drowsiness, unpleasant taste, mild GI disturbances, and orthostatic hypotension.

How it works

Mechanism of action

Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake causing an accumulation of acetaldehyde in the blood producing highly unpleasant symptoms. Disulfiram blocks the oxidation of alcohol through its irreversible inactivation of aldehyde dehydrogenase, which acts in the second step of ethanol utilization. In addition, disulfiram competitively binds and inhibits the peripheral benzodiazepine receptor, which may indicate some value in the treatment of the symptoms of alcohol withdrawal, however this activity has not been extensively studied.

Pharmacodynamics

Disulfiram produces a sensitivity to alcohol which results in a highly unpleasant reaction when the patient under treatment ingests even small amounts of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake, the concentration of acetaldehyde occurring in the blood may be 5 to 10 times higher than that found during metabolism of the same amount of alcohol alone. Accumulation of acetaldehyde in the blood produces a complex of highly unpleasant symptoms referred to hereinafter as the disulfiram-alcohol reaction. This reaction, which is proportional to the dosage of both disulfiram and alcohol, will persist as long as alcohol is being metabolized. Disulfiram does not appear to influence the rate of alcohol elimination from the body. Prolonged administration of disulfiram does not produce tolerance; the longer a patient remains on therapy, the more exquisitely sensitive he becomes to alcohol.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Disulfiram is absorbed slowly from the gastrointestinal tract (80 to 90% of oral dose).

Metabolism

Hepatic.

Drug targets(3)

Proteins and enzymes this drug interacts with in the body

Dopamine beta-hydroxylase

BE0000138

DBH

inhibitor

Specific functioncatalytic activity

Cellular location

Cytoplasmic vesicle, secretory vesicle lumen

General function & pharmacology

Catalyzes the hydroxylation of dopamine to noradrenaline (also known as norepinephrine), and is thus vital for regulation of these neurotransmitters

Aldehyde dehydrogenase, mitochondrial

BE0000133

ALDH2

inhibitor

Specific functionaldehyde dehydrogenase (NAD+) activity

Cellular location

Mitochondrion matrix

General function & pharmacology

Required for clearance of cellular formaldehyde, a cytotoxic and carcinogenic metabolite that induces DNA damage

Aldehyde dehydrogenase family 3 member A2

BE0000600

ALDH3A2

inhibitor

Specific function3-chloroallyl aldehyde dehydrogenase activity

Cellular location

Microsome membrane

General function & pharmacology

Catalyzes the oxidation of medium and long chain aliphatic aldehydes to fatty acids. Active on a variety of saturated and unsaturated aliphatic aldehydes between 6 and 24 carbons in length .
PMID:18035827 PMID:18182499 PMID:22633490 PMID:25047030 PMID:9133646 PMID:9662422

Responsible for conversion of the sphingosine 1-phosphate (S1P) degradation product hexadecenal to hexadecenoic acid PMID:22633490

Metabolizing enzymes(3)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP3A4Cytochrome P450 3A4

substrate

CYP3A5Cytochrome P450 3A5

substrate

CYP2E1Cytochrome P450 2E1

inhibitor

Transporters(1)

Proteins that transport this drug across cell membranes

Bile salt export pump

BE0000703

ABCB11

substrate

Specific functionABC-type bile acid transporter activity

Cellular location

Apical cell membrane

General function & pharmacology

Catalyzes the transport of the major hydrophobic bile salts, such as taurine and glycine-conjugated cholic acid across the canalicular membrane of hepatocytes in an ATP-dependent manner, therefore participates in hepatic bile acid homeostasis and consequently to lipid homeostasis through regulation of biliary lipid secretion in a bile salts dependent manner .
PMID:15791618 PMID:16332456 PMID:18985798 PMID:19228692 PMID:20010382 PMID:20398791 PMID:22262466 PMID:24711118 PMID:29507376 PMID:32203132

Transports taurine-conjugated bile salts more rapidly than glycine-conjugated bile salts .
PMID:16332456
Also transports non-bile acid compounds, such as pravastatin and fexofenadine in an ATP-dependent manner and may be involved in their biliary excretion PMID:15901796 PMID:18245269

Biological pathways(1)

Scientific references(3)

Nash T., Rice W.G.

Efficacies of Zinc-Finger-Active Drugs against<i>Giardia lamblia</i>.

Antimicrobial Agents and Chemotherapy

199842(6):1488-1492. doi: 10.1128/aac.42.6.1488

PMID: 9624499 DOI: 10.1128/aac.42.6.1488

Bouma M.J., Snowdon D., Fairlamb A.H., Ackers J.P.

Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and - resistant Trichomonas vaginalis and Tritrichomonas foetus [In Process Citation].

Journal of Antimicrobial Chemotherapy

199842(6):817-820. doi: 10.1093/jac/42.6.817

PMID: 10052908 DOI: 10.1093/jac/42.6.817

Gaval-Cruz M., Weinshenker D.

mechanisms of disulfiram-induced cocaine abstinence: antabuse and cocaine relapse.

Molecular Interv

2009 Aug9(4):175-87. doi: 10.1124/mi.9.4.6

PMID: 19720750 DOI: 10.1124/mi.9.4.6

ATC classification(3 codes)

ATC P03AA04

ATC P03AA54

ATC N07BB01

Affected organisms(1)

Humans and other mammals

Experimental properties(5)

External resources(2)

RxList Drugs.com

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Disulfiram

DB00822

CAS number

97-77-8

UNII (FDA)

TR3MLJ1UAI

InChI Key (molecular fingerprint)

AUZONCFQVSMFAP-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

5805

ChEBI

4659

PubChem Compound

3117

PubChem Substance

46506008

KEGG Compound

C01692

KEGG Drug

D00131

ChemSpider

3005

BindingDB

50058655

PharmGKB

PA449376

Therapeutic Targets Database

DAP000012

Wikipedia

Disulfiram

ChEMBL

CHEMBL964

ZINC

ZINC000001529266

RxCUI

3554

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2689

GenAtlas

DBH

GeneCards

DBH

GenBank Gene Database

X13255

GenBank Protein Database

30474

Guide to Pharmacology

2486

UniProtKB

P09172

UniProt Accession

DOPO_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:404

GenAtlas

ALDH2

GeneCards

ALDH2

GenBank Gene Database

X05409

GenBank Protein Database

28606

Guide to Pharmacology

2595

UniProtKB

P05091

UniProt Accession

ALDH2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:403

GenAtlas

ALDH3A2

GeneCards

ALDH3A2

GenBank Gene Database

L47162

GenBank Protein Database

1082036

UniProtKB

P51648

UniProt Accession

AL3A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2638

GenAtlas

CYP3A5

GeneCards

CYP3A5

GenBank Gene Database

J04813

GenBank Protein Database

181346

Guide to Pharmacology

1338

UniProtKB

P20815

UniProt Accession

CP3A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:42

GenAtlas

ABCB11

GeneCards

ABCB11

GenBank Gene Database

AF091582

GenBank Protein Database

3873243

Guide to Pharmacology

778

UniProtKB

O95342

UniProt Accession

ABCBB_HUMAN

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 4 months ago(8 Mar 2026)

Structured knowledge from the free knowledge base

Q409665

Wikipedia article

chemical compound

Read on Wikipedia

Research database identifiers

MeSH

D004221

ChEBI

CHEBI:4659

ATC classifications (Wikidata)

P03AA04

N07BB01

Linked open data from Wikidata (Q409665), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.

Source: Q409665CC0 1.0

Updated about 5 hours ago(5 Jul 2026)

Back to medicines

Disulfiram 500mg tablets

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

WHO defined daily dose (DDD)

NICE clinical guidance(2)

Pharmacy stock checkers

Supply & safety information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Metabolism

Clinical essentials

Pharmacology

Deep science
8

Chemical identifiers

Disulfiram

Additional database identifiers

DrugBank citations

Wikipedia article

Research database identifiers

Disulfiram 500mg tablets

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

NHS reimbursement price

WHO defined daily dose (DDD)

Medicines like this

Prescribing statistics

NICE clinical guidance

NICE clinical guidance(2)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & safety information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

Research & evidence

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Metabolism

Clinical essentials

Pharmacology

Deep science8

Chemical identifiers

Disulfiram

Additional database identifiers

DrugBank citations

Wikidata linked open data

Wikipedia article

Research database identifiers

Deep science
8